News - Mergers & Acquisitions, Oncology, North America

Bayer and Onyx file for EU and US approval for expanded use of Nexavar; completes Steigerwald buy

01-07-2013

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) have filed for…

BayerBiotechnologyEuropeMergers & AcquisitionsNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationSteigerwald

Takeda sells non-Colcrys URL Pharma generic business to Sun Pharma; Eisai divests Gliadel Wafer in USA

17-12-2012

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), has entered into a definitive agreement…

Arbor PharmaceuticalsColcrysEisaiGenericsGliadelMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalSun Pharmaceutical IndustriesTakeda PharmaceuticalsURL Pharma

Teva to raise stake in Rexahn; Pfizer completes NextWave deal

28-11-2012

US clinical-stage biopharma company focused on oncology and central nervous system (CNS) therapeutics…

Mergers & AcquisitionsNeurologicalNextWave PharmaceuticalsNorth AmericaOncologyPfizerPharmaceuticalQuillivantResearchRexahn PharmaceuticalsRX-3117Teva Pharmaceutical Industries

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

Shire to acquire FerroKin BioSciences; drops Replagal BLA

16-03-2012

Ireland-headquartered Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire privately-held…

FerroKin BioSciencesMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRare diseasesRegulationReplagalShire

Back to top